tmo has been selected as third
company to produce product for hgen.
for those who like higher priced stocks, tmo
For Thermo Fisher, the partnership with Humanigen represents one of a number of deals struck amid the global pandemic.
Leon Wyszkowski, president, commercial operations and pharma services at Thermo Fisher, told Bioprocess Insider that the company is currently working on over 200 projects developing COVID-19 therapies and vaccines.
In regard to how the company is coping with such demand, he said, “Over the last few months, we have worked closely with our supplier partners, validated alternative sources of supply, monitored our supply chains and expedited transportation modes wherever possible to ensure critical inventories for both COVID and vital non-COVID medicines.”
During its second quarter financials, Thermo Fisher noted that COVID-19-related business alone had contributed $1.3 billion in revenues, with this expected to continue over the coming years.
Less.
